ALB and Hypoglycemia: After a mean follow-up of 7.8 years, the intensive-treatment group had significantly greater reductions in glycated hemoglobin values, blood pressure, serum cholesterol and triglyceride levels, and urinary albumin excretion rate than the conventional-treatment group, resulting in a 50% reduction in the risk of cardiovascular and microvascular events.[130] However, intensive therapy targeting only blood glucose is associated with a significantly increased risk of hypoglycemia, including those requiring pharmacologic intervention for recovery.